Monthly Newsletter

The latest study by VisionGain predicts that the cell-based assays market will reach $4.7 billion in 2016, as improvements in detection technology and sensitivity in drug screening will be among the major drivers in this market.

Drug screening is a costly process confronted with low productivity and challenges with using animals, which limits reproducible results for human relevance. Thus, efforts have been dedicated to developing cell-based high throughput screening (HTS) platforms that can provide more relevant in vivo biological information than biochemical assays and thus reduce the number of animal tests and accelerate the drug discovery process.

Today, cell-based assays are used in more than half of all high-throughput drug screenings for target validation and ADMET (absorption, distribution, metabolism, elimination and toxicity) in the early stage of drug discovery.

For further information click here